Tiziana Life Sciences Ltd (NASDAQ:TLSA) said new biomarker data from an expanded-access program showed its experimental intranasal therapy reduced brain inflammation and was associated with ...

Real-world data show Ocrevus reduced relapse rates and maintained disability stability in relapsing MS over four years.

Monoclonal antibody DMTs, especially anti-CD20 therapies, effectively prevent relapses but have limited impact on progressive MS. Progressive MS involves compartmentalized CNS inflammation, with ...

The Breakthrough Prize has announced its 2025 Laureates in Life Sciences, Fundamental Physics, and Mathematics. Among them are Professors Alberto Ascherio from Harvard University and Stephen Hauser ...

Merck and Mayo Clinic are partnering to use AI technology and large-scale clinical data to speed drug development in MS and ...

Multiple sclerosis (MS) is a chronic disease of the central nervous system that causes disruptions in the flow of information within the brain and between the brain and body, eventually causing ...

HOUSTON & WALTHAM, Mass.--(BUSINESS WIRE)--Biostate AI, a leading innovator in artificial intelligence for RNA sequencing, today announced a strategic partnership with the Accelerated Cure Project ...

Over 95% of the world's adult population is infected with Epstein-Barr virus (EBV), but most people never realize it. The infection often causes few symptoms and then stays in the body for life.

Tyruko ® (natalizumab-sztn), a biosimilar to Tysabri ® (natalizumab), has been made available by Sandoz, according to developer Polpharma Biologics. Tyruko is an integrin receptor antagonist approved ...

WEST PALM BEACH, Fla. — Discontinuing disease-modifying therapies (DMTs) for multiple sclerosis (MS) after prolonged disease stability poses minimal risk for patients aged > 60 years, highlighting the ...

For decades, multiple sclerosis (MS) has been defined primarily by its symptoms, rather than its underlying biology. Now, a new study aims to challenge that approach, presenting evidence that MS may ...

SAN DIEGO — GLP-1s were safe for weight management in patients with multiple sclerosis (MS) but offered no significant protective benefit against disability or disease progression in a new study. A ...